ESPE / ESE 2025

Type 2 diabetes – more common in earlier life!

Pros and cons of metabolic surgery in children and adolescents

Type 1 diabetes – new reason for hope thanks to new technologies

Obesity genes do their work largely through the hypothalamus

Implementation of a screening program for type 1 diabetes in Israel

HYPOMAP & Labradors - a focus on the hypothalamus

Better treatment of diabetes through precision medicine

Obesity and prediabetes in adolescence: how to address this complex issue?

HYPOMAP points to GLP-1 targets in the hypothalamus

The new face of diabetes

Real-world data of liraglutide in childhood and adolescence

The new face of diabetes

Social impacts on childhood and adolescence obesity

Nueva cara de la diabetes

Obesidad y prediabetes en la adolescencia: ¿cómo abordar esta compleja cuestión?

Implementierung eines Screening-Programms von Typ 1 Diabetis in Israel

HYPOMAP & Labradors - den Hypothalamus im Fokus

Renewed strategy in treating proclactinoma

Update on cushing's syndrome

Should we perform dosimetry in RLT of neuroendocrine tumors?

Can we improve patients compliance & adherence to medical treatment in acromegaly?

An old drug that performs better in a new guise!

A new oral compound to treat acromegaly

Un nuovo composto orale per il trattamento dell'acromegalia

Un vecchio farmaco che funziona meglio in una nuova veste!

Strategia rinnovata nel trattamento del proclattinoma

Aggiornamento sulla sindrome di Cushing

Dobbiamo eseguire la dosimetria nella RLT dei tumori neuroendocrini?

Possiamo migliorare la compliance e l'aderenza dei pazienti al trattamento medico nell'acromegalia?

Heterogeneity of graves' disease accros the lifecourse

Thyroid function before and during pregnancy - new assessment and outlook for ATA Guidelines 2025

Just the beginning of a treatment concept for Allan-Herndon-Dudley Syndrome

New data show no risk in thyroid cancer incidence in GLP1-receptor analogue use in diabetes

THESIS survey on the use of thyroid hormones in euthyroid patients

Veligrotug - a new IGF-1 receptor antagonist

Schilddrüsenfunktion vor und während der Schwangerschaft - neue Bewertung und Ausblick auf ATA Guidelines 2025

THESIS-Survey zum Einsatz von Schildrüsenhormonen bei euthyreoden Patienten

Veligrotug - ein neuer IGF-1-Rezeptor-Antagonist

Kein erhöhtes Risiko für Schilddrüsenkrebs bei Verwendung von GLP1-Rezeptor-Analoga bei Diabetes

(Nur) der Anfang eines Behandlungskonzepts für das Allan-Herndon-Dudley-Syndrom

Heterogeneidad de la enfermedad de Graves-Basedow a lo largo de la vida

Reduced strength despite equal mass

First specific therapy for osteogenesis imperfecta

Hypoparathyroidism and kidney

Encaleret in autosomal dominant hypocalcemia type 1

Histomorphometry: research of clinical use

Bone metabolism and fracture risk in hypoparathyroidism

Palopegteriparatide over 4 years in chronic hypoparathyroidism

Pathology influences therapy

Diabetes and fracture risk: what are the causes?

Primary hyperparathyroidism in MEN1: effectiveness of 4D-CT

Characteristics of secondary osteoporosis

Bone fracture risk in children

Competition in the treatment of skeletal dysplasias

Fracture risk in obesity

Osteoclast behavior after discontinuation of anti-RANKL therapy

DEXA or X-ray in osteogenesis imperfecta

Update on osteogenesis imperfecta

Treatment of osteoporosis in primary hyperparathyroidism

European guideline for hypoparathyroidism

Diabetes and fracture risk: clinical aspects

Knochenstoffwechsel und Frakturrisiko bei Hypoparathyreoidismus

Knochenbruchrisiken bei Kindern

Pathologie beeinflusst Therapie

Geringe Kraft bei gleicher Masse

Besonderheiten der sekundären Osteoporose

Therapie der Osteoporose bei primären Hyperparathyreoidismus

Palopegteriparatide über 4 Jahre bei chronischem Hypoparathyreoidismus

Histomorphometrie: Forschung zu klinischen Anwendungen

Hypoparathyreoidismus und Niere

Encaleret bei autosomal-dominanter Hypokalzämie Typ 1

DEXA oder Röngten bei Osteogenesis imperfecta

Update zu Osteogenesis imperfecta

Primärer Hyperparathyreoidismus bei MEN1: Effektivität des 4D-CT

Europäische Guideline für Hypoparathyreoidismus

Osteoklastenverhalten nach Absetzen der Anti-RANKL-Therapie

Diabetes und Frakturrisiko: was sind die Ursachen?

Konkurrenz bei der Therapie der Skeletalen Dysplasie

Erste spezielle Therapie für Osteogenesis imperfecta

Diabetes und Frakturrisiko: klinische Aspekte

Frakturrisiko bei Adipositas

Update on the diagnosis of PCOS in adolescents

Complete hormone count

Thyroid cancer across the lifespan: similar yet different

Discontinuation of denosumab – what is behind the rebound effect?

Concerns with GH replacement based on preclinical studies

Therapeutic approach to growth in noonan syndrome

The genetics of growth

Novel treatment options for CAH

Last evidences on efficacy of CNP treatment for achondroplasia

Oral GH secretagogue LUM-201 is effective in children with moderate GHD after 2 years of treatment

Safety of GH treatment in children and adults

Update on turner syndrome transition

Transition in syndromic diseases requires more than two specialists

ESE guideline update on turner syndrome

Transgender care: staying the course in turbulent times

The usefulness of AMH in prepubertal girls with turner syndrome

Urea-stimulated copeptin

The long shadow of therapy with pituitary hGH

Endocrine aspects in patients with Duchenne Muscular Dystrophy

Hormonal treatment in transgender teenagers

Approach to the diagnosis of DSD

First description of kisspeptin and neurokinin B

Why we need to talk about more than just medicine during transition!

Advances in growth treatment based on molecular mechanisms

Novelty on the treatment of short stature in noonan sydrome

Therapie-Ansatz für das Wachstum beim Noonan-Syndrom

Tratamiento hormonal en adolescentes transexuales

Transgender Behandlung: Kurs halten in stürmischen Zeiten

Novità nel trattamento della bassa statura nella sindrome di noonan

Die Genetik des Wachstums

Warum wir in Dtld. über mehr reden müssen bei der Transition!

Aspetti endocrinologici nei pazienti con Distrofia Muscolare di Duchenne

Transition bei syndromalen Erkrankungen braucht mehr als zwei Fachspezialisten

Schilddrüsenkrebs über die Lebensdauer hinweg: Ähnlich und doch anders

Bedenklichkeit des GH-Ersatzes auf der Grundlage präklinischer Studien

Harnstoff-stimuliertes Copeptin

Nuove opzioni terapeutiche nella iperplasia surrenalica congenita

Recenti evidenze sull'efficacia terapeutica degli analoghi del CNP nell’Acondroplasia

L’utilità dell’AMH nelle bambine prepuberi con sindrome di turner

Vollständige Hormonbestimmung

Aproximación al diagnóstico de DSD

Il Secretagogo LUM-201 si dimostra efficace nel GHD parziale in 2 anni di trattamento

ESE Guideline Update zum Turner Syndrom

Update zur Transition bei Turner Syndrom

Kisspeptin und Neurokinin-B Erstbeschreibung

Absetzen von Denosumab - was steckt hinter dem Rebound Effect?

Sicherheit der GH-Behandlung bei Kindern und Erwachsenen

Actualización sobre el diagnóstico del síndrome de ovario poliquístico en adolescentes

Novità terapeutiche sulle basse stature di origine genetica

Der lange Schatten der Therapie mit pit-hGH

Endocrine disruptors: improvement initiatives

New small molecules for GPCR targeting

Disruptores endocrinos: iniciativas de mejora

Neue Small Molecules für GPCR-Targeting